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Regulatory mechanisms of human hematopoiesis
remain largely uncharacterized. Through expression
profiling of prospectively isolated stem and primitive
progenitor cells as well as committed progenitors
from cord blood (CB), we identified MLLT3 as a
candidate regulator of erythroid/megakaryocytic
(E/Meg) lineage decisions. Through the analysis of
the hematopoietic potential of primitive cord blood
cells in which MLLT3 expression has been knocked
down, we identify a requirement for MLLT3 in the
elaboration of the erythroid andmegakaryocytic line-
ages. Conversely, forced expression of MLLT3 pro-
motes the output of erythroid and megakaryocytic
progenitors, and analysis of MLLT3 mutants sug-
gests that this capacity of MLLT3 depends on its
transcriptional regulatory activity. Gene expression
and cis-regulatory element analyses reveal crossre-
gulatory interactions between MLLT3 and E/Meg-
affiliated transcription factor GATA-1. Taken together,
thedata identifyMLLT3asa regulatorof early erythroid
and megakaryocytic cell fate in the human system.
INTRODUCTION
To maintain blood production throughout life, hematopoietic
stem cells (HSC) must coordinate alternative fates of self-
renewal, multilineage differentiation, quiescence, and apoptosis
(Kondo et al., 2003). Characterizing the regulatory mechanisms
underlying these decisions is important not only in respect of
fundamental biology, but also because of the potential clinical
value of manipulating fate decisions in the context of bone mar-
row transplantation and of treatment of aplastic, dysplastic, and
neoplastic disorders of hematopoiesis. This clinical applicability
underlines the necessity to define and/or verify HSC fate regula-
tory mechanisms in human cells.
Global gene expression profiling of blood stem and progenitor
populations from both mouse (Akashi et al., 2003; Forsberg
et al., 2005; Ivanova et al., 2002; Park et al., 2002; Ramalho-
Santos et al., 2002) and human (Chadwick et al., 2005; Georgan-
tas et al., 2004; Shojaei et al., 2005) yielded candidate molecular
regulators of hematopoiesis and HSC decisions. Moreover, pro-
filing of human primitive hematopoietic populations has indi-
cated regulators of HSC that have been subsequently tested in
the human context (Chadwick et al., 2005; Shojaei et al., 2005).264 Cell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc.Nevertheless, mechanisms by which HSC commit to and
differentiate down the different blood lineages are still debated.
A classical view of the hematopoietic hierarchy (Akashi et al.,
2000; Forsberg et al., 2006; Kondo et al., 1997) proposes that
multipotent progenitors (MPP) undergo a series of binary deci-
sions resulting in successive dichotomic loss of lineage poten-
tials. Thus, MPP originate common myeloid or common
lymphoid progenitors (CMP and CLP, respectively); CMP give
rise to either granulocyte/macrophage progenitors (GMP) or
E/Meg progenitors (MEP); and GMP and MEP resolve into uni-
lineage progenitors. Alternatively, Jacobsen and collaborators
(Adolfsson et al., 2005) proposed that E/Meg commitment can
occur directly from HSC without transit through the CMP; this
idea has gained support from other studies of early hematopoi-
etic hierarchies (Lai and Kondo, 2006; Pronk et al., 2007) and
functional analysis of transcriptional regulators (Yoshida et al.,
2006). Moreover, the study defined a lymphomyeloid primitive
progenitor (LMPP) capable of differentiation down the GM and
the B cell lineages, a population also found by others (Arinobu
et al., 2007). These studies suggest that loss of E/Meg potential
may be an early event in HSCcommitment, and read in a different
light imply that HSC express an incipient E/Meg program. This is,
indeed, discernible from transcriptome analyses (Mansson et al.,
2007).
Known regulatory mechanisms of E/Meg fate decisions cen-
ter on the functional crossantagonism between transcription
factors GATA1 and PU.1 (Swiers et al., 2006). Higher expres-
sion levels of GATA1 determine not only the activation of
E/Meg molecular programs but also act to repress myeloid
decisions by direct interaction with PU.1 and repression of its
transcriptional targets (Nerlov et al., 2000; Zhang et al., 1999).
GATA1 acts in multiprotein complexes with specific transcrip-
tional repressor or activator activities (Rodriguez et al., 2005).
FOG1 (Tsang et al., 1997) is one of its best characterized part-
ners; it participates in either activator or repressor complexes
depending on copartners (Rodriguez et al., 2005) and cellular
contexts (Deconinck et al., 2000). It also plays GATA-indepen-
dent roles in Meg specification (Tsang et al., 1998). The Meg
versus E differentiation decision is regulated by the balance
between EKLF and FLI1 (Starck et al., 2003). EKLF is a tran-
scriptional target of GATA1 (Crossley et al., 1994) required for
definitive erythropoiesis (Nuez et al., 1995). FLI1 is a target of
PU.1 (Starck et al., 1999) highly expressed in Meg cells. While
the crosstalk between GATA1, PU.1 and FOG1, and the down-
stream targets EKLF and FLI1 is relatively well characterized,
little is known about the factors that lie upstream of GATA1
and how they contribute to the initiation of E/Meg commitment
and early differentiation programs.
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MLLT3 Regulates Human Erythro-MegakaryopoiesisMLLT3 (or AF9) was originally identified as a fusion partner of
MLL in acute myeloid leukemia (AML) (Iida et al., 1993); the two
genes are involved in a reciprocal in-frame translocation—
t(9;11)(p22;q23)—that associates most commonly with mono-
blastic (M5) or with myelomonocytic (M4) leukemia and, rarely,
with undifferentiated AML-M1 (Schoch et al., 2003). The MLLT3
protein has two conserved domains at its N and C termini, sep-
arated by a Pro/Ser-rich region that includes the nuclear localiza-
tion signal (NLS) (Figure 2B). The N terminus contains a putative
transactivation YEATS domain (Zeisig et al., 2005). The C termi-
nus is also reported to have transactivation properties (Rubnitz
et al., 1994); it was further shown to interact with transcriptional
repressors such as isoforms of the BCL6 corepressor (BCoR)
(Srinivasan et al., 2003) and the Polycomb homolog MPc3 (Hem-
enway et al., 2001). The fusion protein retains the N-terminal AT
hooks and methyltransferase domain of MLL and the C terminus
of MLLT3. When expressed in mouse HSC or GMP, the MLL/
MLLT3 fusion generates a myeloproliferative disorder (Krivtsov
et al., 2006; Somervaille and Cleary, 2006) morphologically
similar to the human leukemia and with a molecular signature
reminiscent of that of GMP. In contrast with this lineage associ-
ation, early studies of MLLT3 expression in leukemic cell lines
(Iida et al., 1993) showed highest transcript levels in cell lines
of E and Meg potential. An MLLT3 knockout mouse (Collins
Figure 1. Identifying Transcriptional Regulators in Primitive CB
Cells
(A) CD133+G0 and CD133
+G1 cells discriminated on the basis of low/high
staining of double-stranded RNA by Pyronin Y (PY).
(B) Expression of CD38 by CD133+G0 cells (representative plot).
(C) Representative plot of Ki67 staining of sorted CD133+G0 (solid histo-
gram) and CD133+G1 cells (striped histogram).
(D and E) CFC activity of CD133+G0 and G1 cells (mean ± SEM of 7 in-
dependent paired samples).
(F) MLLT3 expression levels in the microarrayed CB samples.
(G) RT-qPCR validation ofMLLT3 expression (n = 2); reactions were run in
duplicate and data normalized to prominin (CD133) expression.
(H) Relative expression of MLLT3 in CB HSC, CMP, MEP, and GMP
analyzed by RT-qPCR; data was normalized to HPRT (hypoxanthine
phosphoribosyl transferase) expression (mean ± SEM of 3 independent
experiments).
et al., 2002) dies perinatally with homeotic-type defects
of cervico-thoracic skeletal specification. The mice do not
have a gross blood phenotype; however, detailed character-
ization of hematopoiesis was not performed.
In this study, we have identified MLLT3 as an early regula-
tor of human E/Meg differentiation. We characterized the
global expression profile of a primitive population of quies-
cent CB cells and identified MLLT3 as one of the most highly
enriched transcripts. Functional and molecular analyses
demonstrate that MLLT3 is a positive regulator of E/Meg
differentiation decisions and suggest that it acts in a regula-
tory circuit including GATA1.
RESULTS
Identification of MLLT3 as a Candidate Regulator
of E/Meg Fate
To identify regulators of human HSC fate, we transcription-
ally profiled quiescent primitive human CB CD133+G0 cells
enriched for long term culture-initiating cell (LTC-IC) activity
(Summers et al., 2004). CD133+G0 cells were sorted by cell-cycle
status using combined DNA and RNA staining (Figure 1A);
CD133+G1 cells served for comparison. The majority of
CD133+G0 cells are CD38
 (Figure 1B), as expected of a HSC-
enriched population. Ki67 staining confirmed the cycling status
of sorted CD133+G0 cells (Figure 1C). Enrichment for LTC-IC
was verified (data not shown) and analysis of colony-forming
cell (CFC) progenitor activity revealed CD133+G0 cells to be
significantly enriched for CFC (Figure 1D) and, in particular, for
more primitive CFC-GEMM (granulocyte-erythroid-monocyte-
megakaryocyte) (Figure 1E). Global transcriptome analysis
(Figure S1A available online) identified 167 transcripts enriched
in CD133+G0 versus CD133
+G1 cells (Figure S1B), including a
number of transcription-associated genes (Figure S1C). Among
these CD133+G0-enriched transcripts, we identified leukemia-
associated MLLT3 as one of the most highly upregulated genes
with a consistent expression pattern across samples (Figures
1F–1G). We interrogated published studies analyzing primitive
HSC-enriched populations of mouse (Forsberg et al., 2005;
Ivanova et al., 2002) and human (Georgantas et al., 2004) and
found MLLT3 reproducibly associated with long-term HSC
(LT-HSC) of adult tissues (Table S1). Given the dual association
of MLLT3 with HSC and E/Meg compartments in a wayCell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc. 265
Cell Stem Cell
MLLT3 Regulates Human Erythro-Megakaryopoiesisreminiscent of the revised hierarchies of hematopoietic differen-
tiation in mouse (Adolfsson et al., 2005), we interrogated progen-
itor compartments of human CB forMLLT3 expression. We pro-
spectively isolated HSC, CMP, GMP, and MEP from CB (Manz
et al., 2002) (Figure S2A); functional analysis indicated high purity
of CMP and GMP, but not of MEP, which consequently should
be regarded as a population enriched for such progenitors (Fig-
ure S2B). MLLT3 expression showed a 2- to 3-fold stepwise
reduction fromHSC to CMP (andMEP) and again to GMP, where
it is present at very low levels (Figure 1H); other transcription
factors with known roles in hematopoiesis (Figures S2C–S2G)
behaved as expected. Taken together with CFC data showing
a significant enrichment in CFC-GEMM and almost exclusive
detection of BFU-E in the CD133+G0 population (Figure 1E), the
results point to a role for MLLT3 in the regulation of commitment
or early differentiation decisions in the E/Meg compartment.
MLLT3 Regulates E/Meg Lineage Fate Decisions
We generated and validated lentiviral vectors for forced
expression (Figures 2A, 2C, and 2D) and expression knockdown
(Figures 2F and 2G) ofMLLT3 in primitive CB cells. Lentiviral vec-
tors encoding N- and C-terminal deletion mutants of MLLT3
(M3DNandM3DC, respectively) were also produced and verified
(Figures 2B–2D).
Figure 2. Lentiviral Constructs Used for Characterization of
MLLT3 Function
(A) Bis-cistronic vector used for forced gene expression (CSIEm). LTR,
long-terminal repeat; RRE, Rev response element; CPPT, central poly-
purine track; IRES, internal ribosomal entry site; emGFP, emerald green
fluorescent protein; WPRE, woodchuck hepatitis virus posttranscrip-
tional regulatory element.
(B) Schematic representation of MLLT3 and its N- and C-terminal deletion
mutants (M3DN and M3DC, which lack the first 102 and the last 94 aa of
the wild-type molecule, respectively). Depicted are the N-terminal YEATS
domain, the nuclear localization signal (NLS), and the C-terminal region;
the arrows mark reported fusion breakpoints to MLL.
(C) Western blot (WB) of total extracts of transfected (first 2 lanes) or
transduced (last 2 lanes) 293T cells loadedwith cell equivalents. Molecular
weights in kDa; arrow, expected MLLT3 size; asterisks indicate expected
mutant size.
(D) WB of total extracts of transduced K562 cells; b-tubulin controls for
loading. Endogenous MLLT3 protein was detectable in the CSIEm lane
on longer exposures.
(E) WB of total extracts of viral packaging or control 293T cells; the sc-265
(N6) antibody specifically detects mouse GATA1 confirming ectopic
expression of the FLAG-tagged molecule (fl-mG1).
(F) Vector used for knockdown MLLT3 expression (LLX). Three human
MLLT3 shRNA targets are represented; restriction sites used for cloning
are shown. J, HIV packaging signal; eGFP, enhanced GFP.
(G) WB of total extracts of 293T cells transduced with LLX or shRNA 1–3
showing different levels of MLLT3 knockdown; b-tubulin controls for
loading.
Forced expression ofMLLT3 in CD34+CD38 cells results
in a significant increase in erythroid progenitors (as read by
BFU-E) at the expense of CFC-GM without affecting more
primitive CFC-GEMM or total colony number (Figures 3A,
3C, and 3D). These changes in colony formation are notmim-
icked by expression of eitherM3DN orM3DC, which behave
similarly to control vector (Figure 3A). The effects of MLLT3
forced expression are broadly similar to those elicited by forced
expression of the E/Meg-affiliated transcription factor GATA1
(Figure 2E) on lineage output in CFC assays (Figure 3I).
MLLT3 expression knockdown in CD34+CD38 cells was
tested using three different shRNA that cause distinct levels of
knockdown (Figures 2F–2G). The two strongest targets produce
an almost complete loss of BFU-E and CFC-GEMM, (Figures 3B,
3E, and 3F and Figures S3A and S3B). The weakest target (Fig-
ures S3A and S3B) produces a significant but less marked
reduction in erythroid output that is not accompanied by loss
of CFC-GEMM. Since the identification of a CFC-GEMM re-
quires the presence of hemoglobinized erythroid cells, the entire
phenotype might be explained by the loss of the erythroid com-
partment. GM colony output is broadly preserved upon MLLT3
expression knockdown (Figure 3B and Figures S3A and S3B).
Forced expression of MLLT3 in total CD34+ cells resulted in
an increase of pure CD41+ colonies (Figure 3G and Figure S3D)
in Meg-CFC assays; these colonies were noted to be smaller
than controls, suggesting accelerated differentiation. In contrast,
knockdown of MLLT3 in CB CD34+CD38 cells resulted in a
reduction of pure CD41+ colonies (Figure 3H and Figure S3C).
More immature mixed CD41+/ colonies (Figure S3E) were not
reproducibly affected in either setting (Figures 3G and 3H and
Figure S3C). Overall, the results support a role for MLLT3 in266 Cell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc.
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that the N- and C-terminal regulatory domains of MLLT3 may be
required for this function.
We then used short-term progenitor engraftment of NOD/
SCID (nonobese diabetic/severe combined immunodeficiency)
b2-microglobulin (b2-m)/ mice (Glimm et al., 2001) to test if
modulation of MLLT3 expression could also influence E/Meg
lineage decisions in vivo. In agreement with the in vitro data,
analysis of the lineage distribution of GFP+ cells 2.5 weeks after
transplantation showed that forced expression of MLLT3 in-
creased erythroid (CD71+) and Meg (CD41+) output in vivo (Fig-
ure 3J). The opposite trend was observed for the erythroid
lineage uponMLLT3 knockdown (Figure 3K); the low basal level
of Meg output in this system virtually prevents detection of fur-
ther putative reductions. Overall, the results suggest that MLLT3
regulates E/Meg lineage decisions in vivo, as well as in vitro.
Analysis of MLLT3 Effects on Proliferation
and Apoptosis
We examined quantitative effects of MLLT3 on apoptosis and
proliferation using suspension cultures. CD34+CD38 cells
transduced with MLLT3 forced expression or knockdown
vectors and their respective controls were cultured in mixed
erythro-myeloid conditions. Increases in total cell number were
Figure 3. MLLT3 Promotes E/Meg Lineage Decisions of Human
Hematopoietic Cells In Vitro and In Vivo
(A and B) CFC activity of CB CD34+CD38 cells transduced with CSIEm,
MLLT3, M3DN, M3DC (A), or LLX, M3sh1 (B) viruses (mean ± SEM of at
least 3 independent experiments).
(CF) Representative photographs of week 2 CFC assay plates. (C)
CSIEm, (D) MLLT3, (E) LLX, (F) M3sh1. Solid circles, CFC-GM; broken
circles, BFU-E.
(G)Meg colony-forming activity of CBCD34+ cells transducedwithCSIEm
or MLLT3 viruses (mean ± SEM of 4 independent paired experiments).
(H) Meg-CFC activity of CB CD34+CD38 cells transduced with LLX or
M3sh1 viruses (mean ± SEM of 3 independent paired experiments).
(I) CFC activity of CB CD34+CD38 cells transduced with CSIEm or
mGATA1 viruses; representation of the relative distribution of colony
types. Data shown is the mean ± SEM of 3 independent paired experi-
ments. Note that E colonies are changed in proportion but not in fre-
quency (CSIEm, 10 ± 2.6:100;mGATA1, 13 ± 4.1:100) and are significantly
and reproducibly smaller in mGATA1 plates, suggesting accelerated
differentiation; frequency of GM and GEMM colonies from mGATA1-
transduced cells is reduced.
(J and K) Short-term progenitor engraftment of NOD/SCID b2-m/mice.
Engraftment was read at 2.5 weeks by analysis of surface markers in
GFP+ cells. Erythroid, CD71+; megakaryocytic, CD41+; lymphoid/myeloid,
CD45+ cells. Each symbol represents one animal; horizontal lines repre-
sent mean percentage of expression for each group. (J) Light gray
diamonds, CSIEm-expressing recipient mice; brown diamonds, MLLT3-
expressing recipient mice.
similar between test and control cultures in both settings
(data not shown). As expected, forced expression of MLLT3
resulted in an increase in erythroid (CD235a+) cells and a
reduction of myeloid (CD13+) output (Figure 4A), whereas
MLLT3 knockdown produced the converse results (Fig-
ure 4D). We specifically checked apoptosis and proliferation
of myeloid and erythroid cells in these cultures. Forced ex-
pression ofMLLT3 was associated with increased apoptosis
of CD13+ cells (Figure 4B), whileMLLT3 knockdown did not sig-
nificantly affect cell death in the myeloid lineage (Figure 4E). This
observation is compatible with the selective loss of CFC-GM
upon sustained high levels of MLLT3 (Figure 3A). Erythroid
CD235a+ cells showed only mildly reduced apoptosis upon
both forced and knockdown MLLT3 expression (Figures 4B
and 4E), and cell death is therefore unlikely to underlie differential
erythroid output. Proliferation of erythroid and myeloid cells was
minimally if at all changed upon forced or knockdown expression
of MLLT3 (Figures 4C and 4F).
Taken together, these data argue against changes in apopto-
sis or proliferation contributing significantly to MLLT3 effects on
regulation of E/Meg fate.
MLLT3 Initiates an E/Meg Program of Gene Expression
We analyzed expression of known lineage-affiliated transcrip-
tion factors in CD34+GFP+ cells derived in culture from primitive
CB cells transduced with control orMLLT3 viruses. In agreement
with the functional data, MLLT3-transduced cells expressed
higher levels of E/Meg-affiliated GATA1, GATA2, SCL, and
GFI1b; GM-associated PU.1,CEBPA, andGFI1were downregu-
lated (Figure 5A).
In order to circumvent the heterogeneity of total CD34+ cells
and tominimize the possibility of the expression results reflectingCell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc. 267
Cell Stem Cell
MLLT3 Regulates Human Erythro-Megakaryopoiesisa cellular mix enriched for E/Meg progenitors, we repeated the
analysis in a more restricted and primitive population of
CD34+CD38GFP+ cells. MLLT3 expression in these cells was
associated with significantly higher levels of GATA1 (Figures
5B and 5C) and GATA2 (Figure 5B and Figure S4A); unlike the
broader cut of CD34+ cells, MLLT3 had no effects on PU.1 ex-
pression (Figure 5B). Forcing expression of MLLT3 in CB GMP,
which have low levels of endogenous MLLT3 (Figure 1H) and
negligible amounts of GATA1 (Figure S2D), augmented GATA1
expression to detectable levels (Figure 5E) with no changes in
GATA2 transcription and minor or no changes in PU.1 expres-
sion (Figure S4B). Taken together, the data suggest that MLLT3
impacts upon E/Meg expression programs including GATA1;
consistent with the functional data, it does not significantly affect
GM-affiliated programs as read by PU.1 expression.
Interestingly, forced expression of GATA1 in CD34+CD38
cells causes amild but significant reduction inMLLT3 expression
(Figure 5D).However, ectopic expressionofGATA1 inGMP led to
an increase in MLLT3 levels (Figure 5E). Thus, while GATA1
clearly modulates MLLT3 expression, it may have opposing
effects at different stages of differentiation. This raises the possi-
bility that MLLT3 and GATA1 may interact in positive or negative
regulatory feedback loops, both of which may be relevant for
normal E/Meg commitment and differentiation progression.
Analysis of Crossregulatory Interactions between
MLLT3 and GATA1
We further explored the regulation of GATA1 expression by
MLLT3 by assessing MLLT3 activity on previously characterized
GATA1 cis-regulatory elements (McDevitt et al., 1997; Nicolis
et al., 1991; Onodera et al., 1997; Ronchi et al., 1997) (Fig-
ure S5A). Erythroleukemic K562 cells transduced with MLLT3
Figure 4. Analysis of Proliferation and Apoptosis in Suspension
Cultures
(A and D) Proportions of myeloid (CD13+) and erythroid (CD235a+) cells
after 6 days in culture in serum-free medium supplemented with cytokines
to support mixed-lineage differentiation.
(B and E) Frequency of apoptosis in erythroid and myeloid cells as deter-
mined by annexin V staining.
(C and F) Proportion of cycling cells in myeloid and erythroid populations
as determined by staining with Ki67. Data is themean ± SEM of 3 indepen-
dent paired experiments.
(Figure 2D) showed significantly increased reporter expres-
sion from the enhancer HS2 region (Figure 6A), which is ac-
tive in definitive erythropoiesis. A milder but significant effect
was also noted on activity of the HS1 enhancer (Figure 6A),
shown to be necessary to drive GATA1 expression in primi-
tive and definitive erythropoiesis. These effects were not
observed in K562 cells transduced with the M3DN mutant
(Figures 2D and 6A) in agreement with the proposed transac-
tivation properties of the YEATS domain (Zeisig et al., 2005).
Unlike GATA1, MLLT3 cis-regulatory elements have not
been characterized. We looked for evolutionary conserved
regions (ECR) spanning 30–35 kb around the start codon,
identified CR with conserved GATA binding sites (Fig-
ure S5B), and analyzedGATA1 binding to these regions using
chromatin immunoprecipitation (ChIP). These studies identi-
fied the uCR9 region upstream of the first exon as an interesting
element, and while it was not significantly enriched in K562 cells
(Figure S5C), it was bound by GATA1 in vivo in the human eryth-
roleukemic cell line TF1 and in the paradigmatic murine erythro-
leukemic cell line MEL (Figure 6B).
Taken together, these analyses of cis-regulatory elements
reinforce the gene expression studies in indicating a role for
MLLT3 in regulating the GATA1 gene and provide further
evidence that GATA1 may itself regulate MLLT3.
DISCUSSION
We have used a global gene expression profiling approach to
identify novel regulators of early cell-fate decisions in human
hematopoiesis. We showed that leukemia-affiliated MLLT3
was one of the most consistently and highly enriched transcripts
in primitive, LTC-IC-enriched CD133+G0 cells from CB. Analysis
of MLLT3 function in primitive human CB cells revealed its role
as a positive regulator of E/Meg differentiation decisions and
suggested that it acts with GATA1 in a previously uncharacter-
ized gene regulatory network controlling early E/Meg lineage
decisions.
Interrogation of published microarray studies profiling primi-
tive murine (Forsberg et al., 2005; Ivanova et al., 2002) and
human (Georgantas et al., 2004) hematopoietic compartments
revealed a consistent association of MLLT3 with HSC or
LT-HSC. Early studies on the expression pattern of MLLT3 had
shown a relatively ubiquitous expression in cell lines, with higher
levels in leukemic cells of Meg and E affiliation (Iida et al., 1993).
Our own analysis of the expression pattern of transcription
factors in prospectively isolated human CB HSC, CMP, MEP,
and GMP showed a progressive decrease from HSC to CMP268 Cell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc.
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that emerges is reminiscent of the recently suggested close
association between HSC and E/Meg progenitors (Adolfsson
et al., 2005). One plausible explanation is that the higher ex-
pression levels of MLLT3 in HSC reflect an E/Meg molecular
signature. MLLT3 may also participate in HSC maintenance in
addition to its role in regulation of E/Meg fate, and we are
currently investigating this possibility.
The absence of effects on lineage fate decisions from two
MLLT3 mutants in which putative transcriptional regulatory
elements have been deleted is compatible with the hypothesis
that MLLT3 influences early E/Meg differentiation decisions
through direct or indirect regulation of gene expression. The pro-
posed regulatory networks (Swiers et al., 2006) behind E/Meg
commitment decisions revolve around the master regulator
GATA1. Several lines of evidence suggest that MLLT3 acts
with or through GATA1. (1) Analysis of MLLT3 effects on
lineage cell fates shows that it broadly phenocopies GATA1.
CFC output of primitive CB cells transduced with either MLLT3
or GATA1 lentiviruses shows a relative increase in E progenitor
activity at the expense of GM colony formation; however,
GATA1-transduced cells show accelerated differentiation com-
pared toMLLT3 or control. This may reflect a role for MLLT3 up-
streamofGATA1, whichwould be compatible with its expression
profile within the hematopoietic hierarchy. (2) Forcing expression
ofMLLT3 in HSC-enriched CD34+CD38 cells or in GMP signif-
icantly increased transcription of GATA1. (3) Conserved GATA1
enhancers showed increased activity in the presence of higher
Figure 5. MLLT3 Induces an E/Meg-Affiliated Molecular
Signature
(A) RT-qPCR analysis of gene expression inCSIEm- orMLLT3-transduced
cells sorted on the basis of GFP andCD34 expression. Data are the results
of 2 independent experiments (experiment 1, dark gray; experiment 2,
light gray; CSIEm, striped bars; MLLT3, solid bars).
(B) RT-qPCR analysis of GATA1, GATA2, SCL, and PU.1 expression in
CD34+CD38GFP+ cells transduced with CSIEm or MLLT3 vectors
(mean ± SEM of at least 3 independent paired experiments).
(C) Representation of the individual paired experiments forGATA1 expres-
sion analysis; each symbol represents one experiment; mean, horizontal
line.
(D) RT-qPCR analysis of MLLT3, GATA2, SCL, and PU.1 expression in
CD34+CD38GFP+ cells transduced with CSIEm or mGATA1 viruses
(mean ± SEM of at least 3 independent paired experiments). GATA1-
transduced CD34+CD38 cells have a reduction in GATA2 expression,
which may reflect accelerated differentiation; PU.1 expression is also
mildly reduced, which is compatible with the functional data and with
previous reports of increased apoptosis of GM cells upon ectopic expres-
sion of GATA1 (Iwasaki et al., 2003).
(E) Semiquantitative RT-PCR analysis of gene expression in GMP trans-
duced with CSIEm, MLLT3, or mGATA1 viruses. Representative ethidium
bromide-stained gel of PCR products.
levels of MLLT3, but not of its M3DNmutant in an erythroleu-
kemic cell line.
Effects of GATA1 on MLLT3 expression are less clear and
may be cell type-dependent. In HSC-enriched CD34+CD38
cells that normally have high levels of MLLT3, forced expres-
sion of GATA1 results in a modest downregulation ofMLLT3
transcription. In GMP, in which levels of MLLT3 are normally
low, ectopic expression of GATA1 results in increased ex-
pression of MLLT3. Furthermore, ChIP analysis of theMLLT3 lo-
cus shows reproducible binding of GATA1 to the newly-identi-
fied uCR9 region in some, but not other, E-affiliated cell lines,
again supporting the idea of cell-type context dependency. In-
deed, GATA1 can act as activator or repressor depending on
the partners with which it forms regulatory complexes (Rodri-
guez et al., 2005). Onemight speculate that sustained high levels
of GATA1 in E/Meg-primed CD34+CD38 cells trigger a differen-
tiation program that requires downregulation of MLLT3 for nor-
mal progression; in GMP, GATA1 expression may derepress
an otherwise silenced E/Meg program in whichMLLT3 is an early
player.
While our results are supportive of a positive regulatory role for
MLLT3 in the E/Meg compartment, our studies in respect of the
GM pathway are less well developed. Forced expression of
MLLT3 significantly reduced GM colony output and increased
apoptosis of myeloid cells in suspension culture. In contrast,
no change in myeloid progenitor activity or cell survival was
observed upon MLLT3 knockdown. Effects on expression of
the GM-affiliated transcriptional regulator PU.1 varied depend-
ing on the cell population analyzed, but transcript levels were
unchanged in more the primitive CD34+CD38 compartment.
Taken together, our results suggest that while MLLT3 may not
play a major role in early PU.1-centered GM lineage decisions,
its sustained expression is incompatible with normal progression
of the GM program.
A further challenge is how to reconcile the role of MLLT3 in
E/Meg lineage decisions with the myeloid lineage affiliation ofCell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc. 269
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MLLT3 Regulates Human Erythro-MegakaryopoiesisMLL-AF9 leukemia. The MLL/MLLT3 fusion protein retains the C
terminus of MLLT3 (Figure 2B) that was suggested to possess
transactivation properties in vitro (Rubnitz et al., 1994) and
shown to interact with transcriptional repressors Pc3 (Hemen-
way et al., 2001) and BCoR (Srinivasan et al., 2003). Studies in
human leukemic cell lines suggest that the monocytic pheno-
type is independent of the MLLT3 C terminus and dependent
on the MLL component (Caslini et al., 2000). In other MLL fusion
proteins, however, evidence suggests that the fusion partner
influences the lineage phenotype of the MLL-associated leuke-
Figure 6. Crossregulatory Interactions between MLLT3 and GATA1
(A) Reporter assays of conservedGATA1 enhancer regions in K562 cells trans-
duced with CSIEm, MLLT3, or M3DN viruses (n = 4 transfections) and in un-
transduced (NEG) K562 cells (n = 2 transfections). Data are the mean ± SEM
of fold increases over minimal promoter activity.
(B) Analysis of in vivo binding of GATA1 to theMLLT3 locus in human (TF1) and
murine (MEL, C88) cell lines. ChIP material was analyzed by SYBRGreen
qPCR; data is the mean ± SEM of 3 independent paired experiments read in
triplicate. Results are represented as enrichments over nonspecific binding
by total rabbit IgG (rab IgG) after normalization to control sequences in the
GAPDH loci.270 Cell Stem Cell 2, 264–273, March 2008 ª2008 Elsevier Inc.mia (Drynan et al., 2005). Our data suggest that the transcrip-
tional regulatory properties of MLLT3 are relevant for normal
hematopoietic differentiation; it is plausible that their disruption
in the context of the leukemic fusion contributes to the leukemic
phenotype even if only in a permissive way. In both contexts, it
will be relevant to consider the recently described association
between MLLT3 and the H3K79methyltransferase DOT1 (Zhang
et al., 2006; Zhang et al., 2007), which also associates with other
MLL-fusion partners (Bitoun et al., 2007; Mueller et al., 2007;
Okada et al., 2005). Since H3K79 methylation can have a mech-
anistic impact on putative leukemogenic gene expression
programs (Mueller et al., 2007; Okada et al., 2005), investigation
of its genomic and locus-specific distribution in the context of
manipulated or leukemia-disrupted expression ofMLLT3 should
help to elucidate regulatory targets and pathways relevant to
lineage affiliation.
EXPERIMENTAL PROCEDURES
Human CB Cell Processing and Progenitor Enrichment
Human CB samples were collected following informed consent and according
to institutional ethical procedures. Mononuclear cells (MNC) were obtained by
Ficoll-Hypaque Plus (Amersham) density centrifugation and enriched for
CD133 or CD34 progenitors by column-based magnetic selection (Miltenyi
Biotec). CD133+ cells were immediately used for downstream assays. CD34+
cells were frozen in StemSpan serum-free expansion medium (SFEM) (Stem
Cell Technologies) with 40% FCS and 10% DMSO. When thawed, cells
were cultured for 6–18 hr prior to use in SFEM with penicillin/streptomycin/
anfothericin and L-Gln (complete SFEM) and SCF, Flt3L, and TPO each at
a concentration of 100 ng/ml (StemSpan CC110, Stem Cell Technologies).
Nucleic Acid Staining
CD133+ cells were washed in Hoechst buffer (HBSS/20 mM HEPES/1 g/l
glucose/10% FCS; pH = 7.2) and stained for DNA (Hoechst 33342 [Ho], Molec-
ular Probes), RNA (Pyronin Y [PY], Polysciences), and CD133 according to
published protocols (Gothot et al., 1997). APC-conjugated CD133/2 (293C3)
antibody (Miltenyi Biotec) was added during the last 10 min of the PY incuba-
tion period. When staining for CD38, CD133+ cells were washed at the end of
the PY incubation period and stained on ice with CD133/2-APC (Miltenyi
Biotec) and CD38-FITC (Dako Cytomation) antibodies. Gates were set for
Holo (G0/G1) CD133
+ single cells; the lowest and highest 15% PY fractions
were sorted as CD133+ G0 and G1 cells, respectively.
Cell Surface Antibody, Ki67, and Annexin V Staining
For sorting of CD34+ and CD34+CD38 cells pre- and postlentiviral transduc-
tion, cells were stained with CD34-APC (BD PharMingen or Miltenyi Biotec)
and CD38-PE (Dako Cytomation). Analysis of differentiation markers used
the following antibodies: PE-conjugated CD13, CD41, and CD235a (Dako
Cytomation); APC-conjugated CD13, CD71, and CD235a (BD PharMingen);
and CD45 (Dako Cytomation). For analysis of Ki67 expression, surface-stained
cells were fixed forR45 min in 1% formaldehyde (Polysciences; EM grade) in
PBS at 4C. Cells were permeabilized in 0.1%Triton X-100 in PBS, and stained
with Ki67-FITC or PE antibody (BD PharMingen) or with the appropriate
isotype control for 45–60 min. For analysis of apoptosis, surface-stained cells
were resuspended in 13 binding buffer and stained with Annexin V-PE (BD
PharMingen) following manufacturer’s protocols.
FACS Instrumentation and Analysis
Cells were sorted on MoFlo or analyzed on CyAn instruments using Summit
software (Dako Cytomation). Nonspecific antibody staining was blocked
with human FcR blocking reagent (Miltenyi Biotec). The appropriate unstained,
isotype, and single-color (or Ho+single color) controls were used for gate
definition and compensation setup.
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MLLT3 Regulates Human Erythro-MegakaryopoiesisLentiviral Constructs and Transductions
Full-length human MLLT3 cDNA (IMAGE clone 5298142), MLLT3 N- and
C-terminal deletion mutants, and FLAG-tagged full-length murine GATA1
were subcloned into amodified version of the pHR-SIN-CSGW-EGFP lentiviral
expression construct (Demaison et al., 2002) (kind gift from A. Thrasher), in
which the EGFP cassette was replaced by IRES-emGFP. Three shRNA
sequences directed at human MLLT3 were designed according to available
protocols and cloned into the pLLX3.7 lentiviral expression construct (Rubin-
son et al., 2003). All constructs were sequence-verified. Detailed cloning strat-
egies are available upon request. Lentiviruses were packaged in HEK293T
cells using a three-plasmid strategy and collected by ultracentrifugation
(Demaison et al., 2002); lentiviral titers were determined by flow cytometric
analysis of GFP levels in transduced 293T cells. Primary CB cells were trans-
duced at a moi of 50–200 in complete SFEM supplemented with CC110 (100
ng/ml) (GMP: 50 ng/ml each of SCF and Flt3L). Cells were washed 18–20 hr
posttransduction and cultured for an extra 72–96 hr (GMP: 24 hr) in either
complete SFEM or complete IMDM/15% FCS supplemented with 50 ng/ml
each of the above cytokines prior to sorting of GFP+ cells. Cultures with serum
were used when sorting CD34+CD38–GFP+ cells (Donaldson et al., 2001).
In Vitro Culture Assays
CFC assays were performed in multipotential methylcellulose-based medium
with recombinant human cytokines (MethoCult GF+ H4435, Stem Cell Tech-
nologies) according to manufacturer’s protocols. Assays were plated in tripli-
cate at a final density of 150 cells/dish. Meg-CFC assays were performed in
collagen-based medium with recombinant human cytokines (MegaCult-C+,
Stem Cell Technologies) according to manufacturer’s instructions. Assays
were plated in quadruplicate; CD34+ and CD34+CD38 cells were plated at
densities of 1000 and 250 cells/culture, respectively. Suspension cultures of
transduced sorted cells were set up in complete SFEM supplemented with
recombinant human cytokines (all from Peprotech): SCF, Flt3L (50 ng/ml);
IL-3, GM-CSF, G-CSF, and M-CSF (10 ng/ml); EPO (10 U/ml).
NOD/SCID b2-m/ Mouse Transplantation Assays
Thawed CB CD34+ cells were transduced for 8 to 9 hr, washed, and injected
into sublethally irradiated (350 cGy) anesthetized NOD/SCID b2 m/ mice
by intratibial route. Mice were sacrificed 2.5 weeks after transplantation.
Bone marrow flushed from 4–6 bones was red blood cell lysed, antibody
stained, and analyzed for surface markers as described above. E, Meg, and
Lymphoid/Myeloid engraftment were defined as %CD71+, CD41+, or CD45+
cells, respectively, in GFP+ cells at equivalent levels of GFP between control
and test animals.
Quantitative RT-PCR Analysis
Equivalent amounts of total RNA were DNase treated (RNase-free DNase,
Promega) and reverse transcribed using Superscript II (Invitrogen). The
cDNA samples were analyzed with either inventoried Taqman gene expression
assays (Applied Biosystems) or in qPCR using SYBR green master mix
(QIAGEN). Primer sequences are available upon request. Expression values
and reaction efficiencies were determined empirically using a dilution series
of mixed human cDNA samples. Relative gene expression was calculated
using the Pfaffl method (Pfaffl, 2001). All reactions were performed in triplicate
unless otherwise indicated.
Chromatin Immunoprecipitation and Analysis of Material
For each ChIP, 1.25 3 107 cells were crosslinked with 1% formaldehyde in
DMEM media without serum for 15 min at room temperature prior to sonica-
tion. Sheared chromatin was incubated with 10 mg antibody overnight and
chromatin-antibody complexes precipitated with Protein-G agarose (Roche).
Antibodies were supplied by Santa Cruz Biotechnology: GATA-1 (M-20,
sc-1234x) and total rabbit IgG (sc-2027). Immunoprecipitated chromatin was
incubated at 65C overnight to reverse the crosslinks and treated with Protein-
ase K, before phenol/chloroform extraction and ethanol precipitation. The
material was analyzed by SYBRGreen qPCR (Applied Biosystems) using
mouse- and human-specific primers to the regions of interest (primer
sequences and cycling conditions are available upon request); all reactions
were performed in triplicate. Expression values and reaction efficiencies
were determined using a dilution series of ChIP input material. Results werenormalized to control regions in the GAPDH locus, and relative expression
was calculated using the Pfaffl method.
Reporter Assays
Plasmids used for the luciferase reporter assayswere a kind gift fromA. Ronchi
and S. Ottolenghi and have been described elsewhere (Bose et al., 2006;
Ronchi et al., 1997). For each assay, 4 3 105 K562 cells (wild-type or trans-
duced with CSIEm, MLLT3 or M3DN viruses) were plated in RPMI 1640
10%FCS and transfected with 800 ng of the plasmid of interest in the presence
of lipofectamine (LF2000, Promega); 8 ng of pRL-TK plasmid were cotrans-
fected in each reaction. Cell extracts were prepared 40 hr later, and double
luciferase activity was determined using the Dual-Luciferase Reporter Assay
System (Promega) according to manufacturers’ instructions. Data were nor-
malized to Renilla luciferase readings to correct for transfection efficiency
and represented relative to minimal promoter activity.
Statistical Analysis
All statistical analyses used two-tailed t tests at a significance value p < 0.05.
ACCESSION NUMBERS
The microarray data are deposited in ArrayExpress under accession number
E-MEXP-1412.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and five figures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/2/3/264/DC1/.
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